# Tissue Regenix: Turning profitable and cash-generative

- Link: https://www.directorstalkinterviews.com/tissue-regenix-turning-profitable-and-cash-generative/4121113844
- Published: 2023-04-06T07:38:08+01:00
- Author: Amilia Stone

**Tissue Regenix Group plc **(LON:TRX) is focused on the development and commercialisation
of two proprietary processing technologies for the repair of soft tissue (dCELL®)
and bone (BioRinse®). It has a broad portfolio of regenerative medicine products
for the biosurgery, orthopaedics and dental markets. 2022 results highlighted the
benefits from recent investment in capacity and commercialisation, with the company
turning EBITDA-positive in 4Q’22. Further strong growth is expected in 2023, with
TRX becoming cash-generative and nearing profitability. Additional operating efficiencies
have been identified, moving Phase 2 of the capacity expansion programme into 2025.

 * **Strategy:** Tissue Regenix is building an international regenerative medicine
   business around its proprietary technology platforms, underpinned by compelling
   clinical outcomes. Phase 1 of its manufacturing capacity expansion programme 
   came on stream in 2021 to satisfy demand from distribution partners for its innovative
   products.
 * **2022 results:** Underlying sales rose 26%, to $24.5m ($19.8m), with growth 
   being seen in all three divisions. Operating efficiencies and tight cost control
   saw TRX become EBITDA-positive in 4Q’22. Gross cash at the period-end was $5.95m,
   and the revolving debt facility has been doubled, to $10m.
 * **Outlook:** Management will continue to build on its “4S” strategy to drive 
   sales growth and [sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news).
   While continuing to drive the performance in the US, TRX is looking to extend
   its geographical reach through commercial distribution agreements elsewhere, 
   making the company profitable and cash-generative.
 * **Risks:** The prolonged effects of the pandemic are evident in the number of
   elective procedures, staff shortages in healthcare institutions and supply chain
   issues, although investment in capacity by TRX has mitigated some of these risks.
   Also, Tissue Regenix will not be immune from global economics and wage inflation.
 * **Investment summary:** Turning EBITDA-positive in 4Q’22 was a major milestone,
   and the leverage effect of expected sales growth in 2023 will become more apparent,
   highlighting the low rating on the shares. An EV/sales multiple of 4x 2024E sales
   generates a valuation of $139m/£112m. The board is proposing a 1-for-100 share
   consolidation to make the shares less unwieldy and to increase their attractiveness
   to investors.

[230405-Hardman-Tissue-Regenix-TRX-Turning-profitable-and-cash-generative](https://www.directorstalkinterviews.com/wp-content/uploads/2023/04/230405-Hardman-Tissue-Regenix-TRX-Turning-profitable-and-cash-generative.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2023/04/230405-Hardman-Tissue-Regenix-TRX-Turning-profitable-and-cash-generative.pdf)

Share on:
